rabbit polyclonal anti human fapα  (Bio-Rad)

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Changes in CXCL12, CXCR4, and FAPα expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Expressing, Irradiation, MANN-WHITNEY

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Correlation of CXC chemokine ligand 12 (CXCL12), CXC chemokine type 4 (CXCR4), and fibroblast activation protein-α (FAPα) expression with clinicopathological factors in 121 patients with locally advanced rectal cancer.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Activation Assay, Expressing

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Images showing immunohistochemical staining of CXCL12, CXCR4, and FAPα in the case of each pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (LARC-nCRT) (A,C,E) and LARC with no nCRT (LARC-no nCRT) (B,D,E). In the case of LARC-nCRT, the expression of CXCL12, CXCR4, and FAPα is higher than in the case of LARC-no nCRT (original magnification 400× ; scale bar= 50 µm).

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Comparison of the levels of CXCL12, CXCR4, and FAPα by immunohistochemical staining among pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (nCRT) (LARC-nCRT) (n = 61), LARC untreated with nCRT (LARC-no nCRT) (n = 60) and high-grade dysplasia of colorectal adenoma (HD) (n = 16). The levels of the three proteins were higher in LARC-nCRT than in LARC-no nCRT or HD (p < 0.001 for each). (A) CXCL12 positivity: 62.3%, 38/61 LARC-nCRT cases; 5.0%, 3/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (B) CXCR4 positivity: 47.5%, 29/61 LARC-nCRT cases; 0.0%, 0/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (C) FAPα positivity: 62.3%, 38/61 LARC-nCRT cases; 25.0%, 15/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Comparison, Immunohistochemical staining, Staining

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Univariate analysis of overall survival and freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Multivariate analysis of overall survival and Freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Kaplan-Meier survival curves-estermates of freedom from recurrence of colorectal cancer in 61 cases of locally advanced rectal cancer (LARC) with neoadjuvant chemoradiotherapy according to plasma membrane expressions of CXCL12, CXCR4 and FAPα in tumor cells. (A) CXCL12, (B) CXCR4, and (C) FAPα.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Clinical Proteomics, Membrane